Hector Falcoff
Hector Falcoff has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Abdelmalek Mouazer
Laboratory of Medical Informatics and Knowledge Engineering in e-Health INSERM Université Sorbonne Paris Nord Sorbonne Université LIMICS Paris France
2 shared publications - Jean-Baptiste Lamy
Sorbonne Université, INSERM, Université Sorbonne Paris Nord, LIMICS, Paris France
2 shared publications - Karima Sedki
Laboratory of Medical Informatics and Knowledge Engineering in e-Health INSERM Université Sorbonne Paris Nord Sorbonne Université LIMICS Paris France
2 shared publications - Sophie Dubois
SFTG Recherche (Société de Formation Thérapeutique du Généraliste) Paris France
2 shared publications - Beat Künzi
Swisspep – Institute for Quality and Research in Healthcare, Postfach – CH 3073 Guemligen, Switzerland
1 shared publication - Catherine Letord
Centre Hospitalier Universitaire de Rouen, Département de Santé numérique, INSERM, Sorbonne Université, Université Sorbonne Paris Nord, Laboratoire d’Informatique Médicale et d’Ingénierie des connaissances en e-Santé, LIMICS, 76000 Rouen, France
1 shared publication
Latest Publications
- Open Access
A randomized simulation trial evaluating ABiMed, a clinical decision support system for medication reviews and polypharmacy management
Background: Medication review is a structured interview of the patient, performed by the pharmacist and aimed at optimizing drug treatments. In practice, medication review is a long and cognitively-demanding task that requires specific knowledge. Clinical practice guidelines have been proposed, but their application is tedious. Methods: We designed ABiMed, a clinical decision support system for medication reviews, based on the implementation of the STOPP/START v2 guidelines and on the visual presentation of aggregated drug knowledge using tables, graphs and flower glyphs. We evaluated ABiMed with 39 community pharmacists during a randomized simulation trial, each pharmacist performing a medication review for two fictitious patients without ABiMed, and two others with ABiMed. We recorded the problems identified by the pharmacists, the interventions proposed, the response time, the perceived usability and the comments. Pharmacists' medication reviews were compared to an expert-designed gold standard. Results: With ABiMed, pharmacists found 1.6 times more relevant drug-related problems during the medication review (p=1.1e-12) and proposed better interventions (p=9.8e-9), without needing more time (p=0.56). The System Usability Scale score is 82.7, which is ranked "excellent". In their comments, pharmacists appreciated the visual aspect of ABiMed and its ability to compare the current treatment with the proposed one. A multifactor analysis showed no difference in the support offered by ABiMed according to the pharmacist's age or sex, in terms of percentage of problems identified or quality of the proposed interventions. Conclusions: The use of an intelligent and visual clinical decision support system can help pharmacists when they perform medication reviews. Our main perspective is the validation of the system in clinical conditions.
Open AccessA randomized simulation trial evaluating ABiMed, a clinical decision support system for medication reviews and polypharmacy management
Background: Medication review is a structured interview of the patient, performed by the pharmacist and aimed at optimizing drug treatments. In practice, medication review is a long and cognitively-demanding task that requires specific knowledge. Clinical practice guidelines have been proposed, but their application is tedious. Methods: We designed ABiMed, a clinical decision support system for medication reviews, based on the implementation of the STOPP/START v2 guidelines and on the visual presentation of aggregated drug knowledge using tables, graphs and flower glyphs. We evaluated ABiMed with 39 community pharmacists during a randomized simulation trial, each pharmacist performing a medication review for two fictitious patients without ABiMed, and two others with ABiMed. We recorded the problems identified by the pharmacists, the interventions proposed, the response time, the perceived usability and the comments. Pharmacists' medication reviews were compared to an expert-designed gold standard. Results: With ABiMed, pharmacists found 1.6 times more relevant drug-related problems during the medication review (p=1.1e-12) and proposed better interventions (p=9.8e-9), without needing more time (p=0.56). The System Usability Scale score is 82.7, which is ranked "excellent". In their comments, pharmacists appreciated the visual aspect of ABiMed and its ability to compare the current treatment with the proposed one. A multifactor analysis showed no difference in the support offered by ABiMed according to the pharmacist's age or sex, in terms of percentage of problems identified or quality of the proposed interventions. Conclusions: The use of an intelligent and visual clinical decision support system can help pharmacists when they perform medication reviews. Our main perspective is the validation of the system in clinical conditions.
- Open Access
Adaptive questionnaires for facilitating patient data entry in clinical decision support systems: Methods and application to STOPP/START v2
Clinical decision support systems are software tools that help clinicians to make medical decisions. However, their acceptance by clinicians is usually rather low. A known problem is that they often require clinicians to manually enter lots of patient data, which is long and tedious. Existing solutions, such as the automatic data extraction from electronic health record, are not fully satisfying, because of low data quality and availability. In practice, many systems still include long questionnaire for data entry. In this paper, we propose an original solution to simplify patient data entry, using an adaptive questionnaire, i.e. a questionnaire that evolves during user interaction, showing or hiding questions dynamically. Considering a rule-based decision support systems, we designed methods for translating the system's clinical rules into display rules that determine the items to show in the questionnaire, and methods for determining the optimal order of priority among the items in the questionnaire. We applied this approach to a decision support system implementing STOPP/START v2, a guideline for managing polypharmacy. We show that it permits reducing by about two thirds the number of clinical conditions displayed in the questionnaire. Presented to clinicians during focus group sessions, the adaptive questionnaire was found "pretty easy to use". In the future, this approach could be applied to other guidelines, and adapted for data entry by patients.
Open AccessAdaptive questionnaires for facilitating patient data entry in clinical decision support systems: Methods and application to STOPP/START v2
Clinical decision support systems are software tools that help clinicians to make medical decisions. However, their acceptance by clinicians is usually rather low. A known problem is that they often require clinicians to manually enter lots of patient data, which is long and tedious. Existing solutions, such as the automatic data extraction from electronic health record, are not fully satisfying, because of low data quality and availability. In practice, many systems still include long questionnaire for data entry. In this paper, we propose an original solution to simplify patient data entry, using an adaptive questionnaire, i.e. a questionnaire that evolves during user interaction, showing or hiding questions dynamically. Considering a rule-based decision support systems, we designed methods for translating the system's clinical rules into display rules that determine the items to show in the questionnaire, and methods for determining the optimal order of priority among the items in the questionnaire. We applied this approach to a decision support system implementing STOPP/START v2, a guideline for managing polypharmacy. We show that it permits reducing by about two thirds the number of clinical conditions displayed in the questionnaire. Presented to clinicians during focus group sessions, the adaptive questionnaire was found "pretty easy to use". In the future, this approach could be applied to other guidelines, and adapted for data entry by patients.
- Open Access
- 27 April 2015
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 65 (634) , e295-e304
Impact of a printed decision aid on patients’ intention to undergo prostate cancer screening: a multicentre, pragmatic randomised controlled trial in primary care
Background Despite recommendations against systematic screening for prostate cancer, 70% of patients still request prostate-specific antigen testing. Aim To assess the impact of a decision aid on patients’ intention to undergo prostate cancer screening. Design and setting Randomised controlled trial with two-arm parallel groups in 86 general practices in urban and rural areas in France. Method Males aged 50–75 years were randomised to receive either the decision aid (intervention group) or usual care (control group). The primary outcome was the proportion of patients’ intending to undergo prostate cancer screening, assessed immediately after reading the decision aid. The reasons underlying their choice were elicited and the proportion of patients citing each reason to undergo, or not undergo, prostate cancer screening were compared between the two arms. Results A total of 1170 patients were randomised (588 in the intervention arm) from November 2012 to February 2013. The proportion of patients who intended to be tested for prostate cancer in the intervention arm (123 patients [20.9%]) was significantly reduced compared with the control arm (57 patients [9.8%]) (difference 11.1%, 95% confidence interval [CI] = 7.0 to 15.2, P <0.0001). In the intervention group, a lower proportion of individuals expressed that cancer screening would protect them from the disease, compared with the control group ( P <0.0001), while a greater proportion of individuals stated that prostate cancer screening would not benefit their health ( P <0.0001) and may involve procedures with harmful side effects ( P = 0.0005). Conclusion The decision aid improved participants’ informed decision making and reduced their intent to undergo prostate cancer screening.
- 27 April 2015
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 65 (634) , e295-e304
Open AccessImpact of a printed decision aid on patients’ intention to undergo prostate cancer screening: a multicentre, pragmatic randomised controlled trial in primary care
Background Despite recommendations against systematic screening for prostate cancer, 70% of patients still request prostate-specific antigen testing. Aim To assess the impact of a decision aid on patients’ intention to undergo prostate cancer screening. Design and setting Randomised controlled trial with two-arm parallel groups in 86 general practices in urban and rural areas in France. Method Males aged 50–75 years were randomised to receive either the decision aid (intervention group) or usual care (control group). The primary outcome was the proportion of patients’ intending to undergo prostate cancer screening, assessed immediately after reading the decision aid. The reasons underlying their choice were elicited and the proportion of patients citing each reason to undergo, or not undergo, prostate cancer screening were compared between the two arms. Results A total of 1170 patients were randomised (588 in the intervention arm) from November 2012 to February 2013. The proportion of patients who intended to be tested for prostate cancer in the intervention arm (123 patients [20.9%]) was significantly reduced compared with the control arm (57 patients [9.8%]) (difference 11.1%, 95% confidence interval [CI] = 7.0 to 15.2, P <0.0001). In the intervention group, a lower proportion of individuals expressed that cancer screening would protect them from the disease, compared with the control group ( P <0.0001), while a greater proportion of individuals stated that prostate cancer screening would not benefit their health ( P <0.0001) and may involve procedures with harmful side effects ( P = 0.0005). Conclusion The decision aid improved participants’ informed decision making and reduced their intent to undergo prostate cancer screening.
- Open Access
- 5 October 2012
- Published by Springer Nature in BMC Family Practice
- Vol. 13 (1) , 96
Cardiovascular risk management in patients with coronary heart disease in primary care: variation across countries and practices. An observational study based on quality indicators
Primary care has an important role in cardiovascular risk management (CVRM) and a minimum size of scale of primary care practices may be needed for efficient delivery of CVRM . We examined CVRM in patients with coronary heart disease (CHD) in primary care and explored the impact of practice size. In an observational study in 8 countries we sampled CHD patients in primary care practices and collected data from electronic patient records. Practice samples were stratified according to practice size and urbanisation; patients were selected using coded diagnoses when available. CVRM was measured on the basis of internationally validated quality indicators. In the analyses practice size was defined in terms of number of patients registered of visiting the practice. We performed multilevel regression analyses controlling for patient age and sex. We included 181 practices (63% of the number targeted). Two countries included a convenience sample of practices. Data from 2960 CHD patients were available. Some countries used methods supplemental to coded diagnoses or other inclusion methods introducing potential inclusion bias. We found substantial variation on all CVRM indicators across practices and countries. We computed aggregated practice scores as percentage of patients with a positive outcome. Rates of risk factor recording varied from 55% for physical activity as the mean practice score across all practices (sd 32%) to 94% (sd 10%) for blood pressure. Rates for reaching treatment targets for systolic blood pressure, diastolic blood pressure and LDL cholesterol were 46% (sd 21%), 86% (sd 12%) and 48% (sd 22%) respectively. Rates for providing recommended cholesterol lowering and antiplatelet drugs were around 80%, and 70% received influenza vaccination. Practice size was not associated to indicator scores with one exception: in Slovenia larger practices performed better. Variation was more related to differences between practices than between countries. CVRM measured by quality indicators showed wide variation within and between countries and possibly leaves room for improvement in all countries involved. Few associations of performance scores with practice size were found.
- 5 October 2012
- Published by Springer Nature in BMC Family Practice
- Vol. 13 (1) , 96
Open AccessCardiovascular risk management in patients with coronary heart disease in primary care: variation across countries and practices. An observational study based on quality indicators
Primary care has an important role in cardiovascular risk management (CVRM) and a minimum size of scale of primary care practices may be needed for efficient delivery of CVRM . We examined CVRM in patients with coronary heart disease (CHD) in primary care and explored the impact of practice size. In an observational study in 8 countries we sampled CHD patients in primary care practices and collected data from electronic patient records. Practice samples were stratified according to practice size and urbanisation; patients were selected using coded diagnoses when available. CVRM was measured on the basis of internationally validated quality indicators. In the analyses practice size was defined in terms of number of patients registered of visiting the practice. We performed multilevel regression analyses controlling for patient age and sex. We included 181 practices (63% of the number targeted). Two countries included a convenience sample of practices. Data from 2960 CHD patients were available. Some countries used methods supplemental to coded diagnoses or other inclusion methods introducing potential inclusion bias. We found substantial variation on all CVRM indicators across practices and countries. We computed aggregated practice scores as percentage of patients with a positive outcome. Rates of risk factor recording varied from 55% for physical activity as the mean practice score across all practices (sd 32%) to 94% (sd 10%) for blood pressure. Rates for reaching treatment targets for systolic blood pressure, diastolic blood pressure and LDL cholesterol were 46% (sd 21%), 86% (sd 12%) and 48% (sd 22%) respectively. Rates for providing recommended cholesterol lowering and antiplatelet drugs were around 80%, and 70% received influenza vaccination. Practice size was not associated to indicator scores with one exception: in Slovenia larger practices performed better. Variation was more related to differences between practices than between countries. CVRM measured by quality indicators showed wide variation within and between countries and possibly leaves room for improvement in all countries involved. Few associations of performance scores with practice size were found.